| Genoptix plunges as spending hurts 1Q profit (AP) Shares of Genoptix Inc. sank Friday after the diagnostic services company surprised Wall Street by posting lower first-quarter profit on a jump in spending. us.rd.yahoo.com |
Drug Approval Could Spur IPO Swiss pharmaceutical company Nycomed said the European health regulator approved lung drug Daxas in patients suffering from smoker's lung, a move that could spur the private equity-backed company's IPO plans. online.wsj.com |
Illumina’s 2Q Earnings Report: A Cheat Sheet Wall Street Cheat Sheet submits: By Elliot TurnerYesterday after the bell, Illumina (ILMN), a leader in genome analysis and sequencing, and a recent Tech Cheat Sheet focus stock, reported a blockbuster quarter: EPS checked in at $0.26/share against estimates of $0.23/share on revenues of $212 million, comfortably above the $194 million estimate. For the 2010 fiscal year, management projects earnings per share of $0.93-$1.00, raising the bottom line of their estimate, and revenues of $852 million against the previously projected $825 million.Complete Story » seekingalpha.com |
Forest Settles Criminal Investigation Over Illegal Drug Marketing: Biotech's Latest Mishaps The Burrill Report submits: Forest Pharmaceuticals (FRX) has agreed to pay more than $300 million to settle charges stemming from a multiyear criminal investigation by the U.S. Food and Drug Administration over illegal marketing of drugs. The FDA, working in coordination with the U.S. Department of Justice, said that Forest Pharmaceuticals entered into a plea agreement in which the company accepted responsibility for criminal actions including distribution of an unapproved new drug, distribution of a misbranded drug, and obstruction of an FDA inspection. The settlement included $164 million in criminal penalties. Charges against Forest were primarily for its marketing of Levothroid, an unapproved drug used for the treatment of hypothyroidism. Arena Pharmaceutical’s (ARNA) shares plunged nearly 40 percent after a U.S. Food and Drug Administration advisory committee rejected its proposed weight loss drug lorcaserin. The reviewers expressed concern that potential risks of long-term use outweighed its benefit of modest weight loss. A briefing document issued two days earlier noted that the drug caused cancer in lab rats and succeeded by just “a slim margin” in meeting the FDA’s expectations for weight management. That news spurred a sell-off that drove Arena's shares down 38 percent as investors fretted over how the FDA's Endocrinologic & Metabolic Drugs Advisory Committee would vote. The committee’s recommendation often guides the FDA’s final decision on whether or not to grant marketing approval. Complete Story » seekingalpha.com |
Alere Health Executives and Clients Share Insights in How to Enroll and Engage Participants in Health and Wellness Programs [PR Newswire] - Sharing best-in-class strategies on how to enroll and engage employees and health plan members in health and wellness programs will be the key focus of a panel discussion featuring clients of Alere Health at the Care Continuum Alliance's Forum 10 & Integrated Care Summit, held October 13 – 15 in Washington, D.C.  Alere client leaders from The Procter & Gamble Company and Scripps Health will share their experiences and strategies for enrollment and engagement during the panel discussion scheduled for Thursday, October 14, 1:45 to 2:45 p.m. us.rd.yahoo.com |